Business
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":" DENVER--(BUSINESS WIRE)--\nTriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology.\n\n\nThe study evaluated the delivery and biologic activity of nelitolimod, an investigational Toll-like receptor 9 (TLR9) agonist, when administered using PEDD, compared with conventional delivery approaches. The research examined therapeutic distribution in a porcine liver tumor model and anti-tumor activity in murine liver metastasis models.\n\n\nKey findings from the study include:\n\n\n\nImproved intratumoral delivery: PEDD administration with the TriNav® Infusion System resulted in significantly greater distribution of nelitolimod within and around tumors compared with delivery through a conventional microcatheter in an Oncopig model of hepatic tumors\n\n\n\nEvidence of enhanced immune activity: Treatment using PEDD was associated with reduced levels of immunosuppressive myeloid-derived suppressor cells (MDSCs) and increased infiltration of cytotoxic CD8+ T cells within the tumor microenvironment.\n\n\n\nReduced tumor growth: In a murine liver metastasis model, nelitolimod delivered using PEDD significantly reduced tumor growth compared with systemic administration at key time points during the study.\n\n\n\nPotential impact of delivery on immunotherapy performance: The findings support the concept that improving therapeutic distribution within tumors may influence both immune activation and anti-tumor activity.\n\n\n“This study highlights the critical role that delivery plays in determining how effectively therapies engage the tumor microenvironment, particularly for immunotherapies designed to activate local immune responses,” said Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences. “By combining PEDD-enabled delivery with nelitolimod, we observed improved distribution within tumors along with encouraging signals of immune activation and anti-tumor activity in these preclinical models. Importantly, these findings illustrate the broader potential of PEDD as a...